Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

about

miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.GAPLINC is a predictor of poor prognosis and regulates cell migration and invasion in osteosarcoma

P2860

Q47736139-C383BBC7-02B3-416C-A611-4612FA09D9F4 Q49584310-0EE2E810-9D6C-4C37-A1B3-ECC0590F7244 Q57287602-FFDDA65D-151C-49BA-9791-3DD7689AEF54

P2860

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

Item

http://www.wikidata.org/entity/Q39229404

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@en

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@nl

type

Item

label

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@en

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@nl

prefLabel

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@en

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@nl

P1476

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

@en

P2093

Cindy L Schwartz

http://www.w3.org/2001/XMLSchema#string

Douglas J Harrison

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Systemic therapy for osteosarcoma and Ewing sarcoma

Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good R

Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Cisplatin and hypomagnesemia.

Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features.

Programmed cell death ligand 1 expression in osteosarcoma.

Osteosarcoma treatment - where do we stand? A state of the art review.

Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.

P2888

s11864-017-0464-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11864-017-0464-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28391422

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

about

P2860

P2860

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921